Baseline characteristics of the included patients with SLE
| Characteristics | Women with SLE (n=12) |
| ACR criteria* | |
| Malar rash | 3 (25) |
| Discoid rash | 2 (16) |
| Photosensitivity | 4 (33) |
| Oral ulcers | 3 (25) |
| Arthritis | 10 (83) |
| Serositis | 1 (8.3) |
| Renal disorder | 7 (58) |
| Neurological disorder | 0 (0) |
| Haematological disorder | 6 (50) |
| Immunological disorder | 9 (75) |
| ANA | 12 (100) |
| Disease duration at inclusion (years)† | 8.5 (0.5–15) |
| SLEDAI-2K score during pregnancy†‡ | 1 (0–2) |
| Ever anti-dsDNA* | 10 (83) |
| Ever antiphospholipid antibodies*§ | 5 (42) |
| Antiphospholipid syndrome* | 0 (0) |
| Medication at pregnancy onset* | |
| Hydroxychloroquine | 11 (92) |
| Low molecular weight heparin¶ | 6 (50) |
| Acetylsalicylic acid¶ | 12 (100) |
| Any immunosuppressant medication** | 11 (92) |
| Azatioprin | 5 (42) |
| Prednisone | 5†† (42) |
*Data presented as n (%).
†Data presented as median (range).
‡Missing data for four participants.
§Including anti-β2-glycoprotein 1 antibody (IgA, IgG and IgM), anticardiolipin antibody (IgA, IgG and IgM) and lupus anticoagulans (dRVVT).
¶LMWH in four patients at pregnancy start and an additional two patients during pregnancy. Acetylsalicylic acid in nine patients at pregnancy start and an additional three patients during pregnancy.
**Including azatioprin and prednisone.
††Dose range 2.5–5.0 mg/day.
ACR, American College of Rheumatology; SLEDAI-2K, Systemic Lupus Disease Activity Index 2000.